← back to search

Cun Wang

Shanghai Jiao Tong University · CN
Area of research
Molecular Biology · Hepatology · organoid drug screen
Research interest
Research interests include Advanced biosensing and bioanalysis techniques, Hepatocellular Carcinoma Treatment and Prognosis, RNA modifications and cancer, and Ferroptosis and cancer prognosis.
h-index
44
citations
8,354
works
130
NIH funding
primary concept
Biology
email

Recent publications

CLIM-TIME links genetic cancer drivers to immune landscapes.
2026cited by 0position: contributordoi
Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1<sup>+</sup> TAMs.
2026cited by 0position: contributordoi
Author response: Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs
2026cited by 0position: contributordoi
Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs
2026cited by 0position: contributordoi
Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs
eLife 2026cited by 0position: contributordoi
Deciphering the role of the MALT1-RC3H1 axis in regulating GPX4 protein stability.
2025cited by 10position: contributordoi
DYRK1A-TGF-β signaling axis determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma
Developmental Cell 2025cited by 9position: lastdoi
Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs and CD8+ T cells
2025cited by 2position: contributordoi
Reply to Mishima et al.: MALT1 modulates GPX4 expression by regulating its stability.
2025cited by 0position: contributordoi
Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs and CD8+ T cells
2025cited by 0position: contributordoi
Author response: Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs and CD8+ T cells
2025cited by 0position: contributordoi
Author response: Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs and CD8+ T cells
2025cited by 0position: contributordoi
Precision treatment in advanced hepatocellular carcinoma
Cancer Cell 2024cited by 372position: middledoi
Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy
Cancer Cell 2024cited by 65position: lastdoi
Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy
Cancer Cell 2024cited by 63position: contributordoi
Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs
Gastroenterology 2024cited by 47position: lastdoi
Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs
Gastroenterology 2024cited by 45position: contributordoi
SSRI antidepressant citalopram reverses the Warburg effect to inhibit hepatocellular carcinoma by directly targeting GLUT1
Cell Reports 2024cited by 23position: middledoi
Deciphering the role of the MALT1–RC3H1 axis in regulating GPX4 protein stability
Proceedings of the National Academy of Sciences 2024cited by 12position: lastdoi
Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1 <sup>+</sup> TAMs
2024cited by 0position: contributordoi
Evolving therapeutic landscape of advanced hepatocellular carcinoma.
2023cited by 531position: contributordoi
Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS<sup>G12D</sup> inhibitor efficacy in KRAS<sup>G12D</sup>-mutated colorectal cancer.
2023cited by 57position: contributordoi
Identification of a Novel Ferroptosis Inducer with Dual Modulatory Effects on GPX4 Activity and Stability
bioRxiv (Cold Spring Harbor Laboratory) 2023cited by 1position: lastdoi
Combating inconsistent evaluation of intra-tumor immune status by a novel transcriptomic signature in hepatocellular carcinoma.
2023cited by 0position: contributordoi
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Nature Reviews Gastroenterology & Hepatology 2022cited by 700position: lastdoi
A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer.
2022cited by 131position: contributordoi
Long noncoding RNA LHFPL3-AS2 suppresses metastasis of non-small cell lung cancer by interacting with SFPQ to regulate TXNIP expression
Cancer Letters 2022cited by 44position: middledoi
Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy
Molecular Cancer 2022cited by 38position: middledoi
EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma.
2022cited by 5position: contributordoi
Author response: A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer
2022cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Wenxin Qin · Peking University33 papers (2014–2025) · 24 papers (2021–2026)René Bernards · Oncode Institute18 papers (2018–2025)Haojie Jin · Kunming University of Science and Technology15 papers (2014–2021)Guang‐Zhi Jin · Second Military Medical University11 papers (2014–2024)Chen Yang · Hunan University of Traditional Chinese Medicine11 papers (2017–2024)Shu-Heng Jiang · SpringerNature9 papers (2024–2026)Kaiyuan Song · Shanghai Jiao Tong University9 papers (2024–2026)Rong-Kun Li · Elsevier, Inc.9 papers (2024–2026)Jun Li · Nanjing University of Chinese Medicine9 papers (2024–2026)Shan Zhang · Shanghai Jiao Tong University9 papers (2024–2026)Siying Wang · Nanjing Tech University9 papers (2019–2022)Ming Yao · Northeast Petroleum University8 papers (2014–2022)Jia He · Service de Santé des Armées7 papers (2017–2024)Chengtao Yu · Shanghai Cancer Institute6 papers (2019–2022) · 6 papers (2021–2025)Fangyu Zhao · University of Chinese Academy of Sciences6 papers (2014–2020)Zhuoan Cheng · Soochow University6 papers (2017–2022)Chong Sun · German Cancer Research Center6 papers (2021–2024)Roderick L. Beijersbergen · Rockefeller University6 papers (2018–2021)